Jun 2026 (Q2 FY26) — Aug 6, 2026
Nephros Q2 FY26 — Record Revenue and Profitability Driven by Broad-Based Growth
Read the full callNephros (NEPH) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Nephros earnings: last reported Thu, 6 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 6.0 | +36.2% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | 20.2 | +14.6 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | 1.2 | +405.1% YoY | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. |
Price
$3.68 +0.82% · +$0.03
Performance −24.7% 1Y
1Y: $4.89 on 17 Oct 2025 → $3.68. High $5.79 (4 Dec 2025), low $2.78 (7 Apr 2026).
- Previous close
- $3.65
- 52-week range
- $2.78 – $5.79
- One year
- −29.77%
Overview
- Symbol
- NEPH
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Nephros earnings calls (NEPH)
Financials
What the filings say
Net profit, year on year: +405% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 4 | 4 | 5 | 4 | 5 | 5 | 5 | 6 |
| Operating profit | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 |
| Operating margin | 5.9% | 8.2% | 11.6% | 5.6% | 6.6% | 0.4% | 1.9% | 20.2% |
| Other income | -0 | 0 | -0 | -0 | 0 | 0 | 0 | -0 |
| Interest | — | 0 | — | 0 | — | 0 | — | 0 |
| Profit before tax | 0 | — | — | 0 | 0 | 0 | — | 1 |
| Tax rate | 0.0% | — | — | 3.7% | 0.9% | 0.0% | — | 1.1% |
| Net profit | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 |
| EPS ($ per share) | 0.02 | — | 0.05 | 0.02 | 0.03 | — | 0.01 | 0.11 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | -124 | -127 | -132 | -136 | -143 | -144 | -144 | -143 |
| Total liabilities | 4 | 4 | 3 | 3 | 2 | 4 | 3 | 3 |
| Fixed assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total assets | 11 | 12 | 19 | 18 | 11 | 12 | 11 | 14 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -4 | -2 | -7 | -1 | -3 | 1 | -0 | 2 |
| Cash from investing | -1 | -0 | -0 | -0 | -0 | -0 | -0 | 0 |
| Cash from financing | 7 | 2 | 11 | 0 | 0 | -0 | -0 | -0 |
| Net cash flow | 2 | -0 | 4 | -1 | -3 | 1 | -1 | 2 |
| Capital expenditure | — | -0 | -0 | -0 | -0 | -0 | -0 | — |
| Free cash flow | — | -2 | -7 | -1 | -3 | 1 | -1 | — |
Insider filings
14 filings between Nov 10, 2025 and Sep 14, 2026.
Open market
decisions to buy or sellNobody bought or sold NEPH on the open market in this window. The filings below are 6 awards, 3 option exercises and 5 other filings.
Compensation
not trading decisions- 6
- Award — granted as compensation
- 3
- Option exercise — converted options into shares
Latest filings (16)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Sep 14, 2026 | Amron Arthur H Director | Other | 17,749 | $0 |
| Sep 14, 2026 | WEXFORD CAPITAL LP 10% owner | Other | 22,710 | $89.7K |
| Sep 14, 2026 | WEXFORD CAPITAL LP 10% owner | Other | 3,355,111 | $0 |
| Sep 14, 2026 | Amron Arthur H Director | Other | 22,710 | $89.7K |
| Sep 14, 2026 | Amron Arthur H Director | Other | 2,836 | $0 |
| Aug 18, 2026 | WEXFORD CAPITAL LP 10% owner | Option exercise | 812 | $2.9K |
| Aug 12, 2026 | Amron Arthur H Director | Award | 2,418 | $0 |
| May 11, 2026 | Amron Arthur H Director | Award | 3,574 | $0 |
| Mar 23, 2026 | Banks Robert R. Jr. President and CEO | Option exercise | 120,000 | $172.8K |
| Mar 23, 2026 | Krandel Judy Chief Financial Officer | Option exercise | 68,861 | $117.8K |
| Mar 16, 2026 | Amron Arthur H Director | Award | 3,610 | $0 |
| Nov 10, 2025 | Amron Arthur H Director | Award | 5,391 | $0 |
| Nov 10, 2025 | Nettis Lisa Marie Director | Award | 1,622 | $0 |
| Nov 10, 2025 | Spandow Oliver J. Director | Award | 8,036 | $0 |
| Jan 1, 2025 | Amron Arthur H Director | Award | 22,418 | $0 |
| Jan 1, 2025 | Spandow Oliver J. Director | Award | 33,241 | $0 |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for NEPHROS INC
Free account. Everything above stays public.
Write why you follow NEPHROS INC and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading